Monoclonal antibodies against PD-1 have demonstrated efficacy in the clinical treatment of melanoma, non-small cell lung cancer and renal cell carcinoma [14] and are one of the most important treatment agents for melanoma [15]. Here, PDCD1 is linked to melanoma.